ELAB PMGC Holdings Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1840563 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-98.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin27.5%
Operating margin—
Net margin-275.7%
FCF margin-207.8%
EBITDA margin—
Returns
ROE-129.1%
ROA-18.0%
ROIC (approx.)—
Asset turnover0.07x
Leverage & solvency
Liabilities / assets15.8%
Debt / equity0.00x
Current ratio1.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue21.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $590,084 | — | $1.71M | $766,277 |
| Cost of revenue | $404,770 | — | $1.71M | $318,968 |
| Gross profit | $185,314 | — | $1.13M | $447,309 |
| R&D expense | $147,010 | $104,654 | $7,410 | $228,747 |
| SG&A expense | $2.24M | $1.09M | $347,653 | $1.02M |
| Interest expense | $257,630 | $735,197 | $19,525 | $2,629 |
| Pretax income | -$7.75M | -$4.02M | — | — |
| Income tax | $30,972 | — | — | — |
| Net income | -$7.75M | -$6.25M | -$4.30M | -$1.80M |
| EPS (basic) | — | — | -0.40 | -0.19 |
| EPS (diluted) | — | — | -0.40 | -0.19 |
| Balance sheet | ||||
| Cash & equivalents | $5.40M | $3.98M | $3.33M | $1.15M |
| Short-term investments | $572,054 | — | — | — |
| Receivables | $245,423 | $5,276 | $3,072 | $12,854 |
| Inventory | $95,098 | — | $495,667 | $230,145 |
| Current assets | $6.87M | $6.05M | $4.92M | $1.55M |
| PP&E, net | $885,520 | $1,087 | $1,741 | $53,119 |
| Goodwill | $977,774 | — | — | — |
| Intangibles | $2.89M | $2.80M | — | — |
| Total assets | $12.87M | $8.99M | $5.19M | $1.89M |
| Current liabilities | $3.94M | $1.80M | $1.30M | $588,272 |
| Total liabilities | $5.03M | $2.33M | $1.36M | $760,873 |
| Shareholders' equity | $7.84M | $6.66M | $3.83M | $1.13M |
| Shares outstanding | 8,070 | 5,226 | 12,384 | 9.57M |
| Cash flow statement | ||||
| Operating cash flow | -$5.93M | -$5.49M | -$4.56M | -$1.59M |
| Capital expenditure | $442,255 | $9,160 | $11,191 | — |
| Free cash flow | -$6.38M | -$5.50M | -$4.57M | — |
| Investing cash flow | -$2.77M | -$610,564 | -$11,191 | -$32,027 |
| Financing cash flow | $10.12M | $6.76M | $6.74M | $2.36M |
| Depreciation & amortization | $96,145 | $546 | $11,649 | $6,512 |
| Stock-based compensation | -$19,160 | $97,167 | $487,738 | $171,869 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.